Cinthia E Jannes Selected Research

Lipids

1/2023	Cardiovascular disease onset in old people with severe hypercholesterolemia.
3/2022	Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort.
1/2020	Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia.
1/2019	Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.
10/2018	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
11/2014	The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cinthia E Jannes Research Topics

Disease

14	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 03/2022 - 11/2014
6	Cardiovascular Diseases (Cardiovascular Disease) 03/2021 - 01/2017
4	Hypertension (High Blood Pressure) 10/2018 - 09/2015
3	Atherosclerosis 01/2021 - 12/2019
3	Dyslipidemias (Dyslipidemia) 01/2021 - 11/2014
2	Inflammation (Inflammations) 01/2021 - 12/2019
2	Myocardial Infarction 01/2019 - 10/2018
2	Xanthomatosis (Xanthoma) 01/2017 - 01/2017
1	Hypercholesterolemia 01/2023
1	Homozygous Familial Hypercholesterolemia 10/2020
1	Unstable Angina 01/2019
1	Stroke (Strokes) 01/2019
1	Obesity 10/2018
1	Inborn Genetic Diseases (Disease, Hereditary) 10/2018
1	Arcus Senilis 01/2017
1	Coronary Disease (Coronary Heart Disease) 09/2015

Drug/Important Bio-Agent (IBA)

7	oxidized low density lipoproteinIBA 03/2022 - 01/2017
6	LipidsIBA 01/2023 - 11/2014
5	LDL CholesterolIBA 03/2022 - 10/2020
3	CalciumIBA 01/2020 - 01/2017
3	CholesterolIBA 10/2018 - 09/2015
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2019
1	Adenosine Monophosphate (AMP)IBA 01/2022
1	LDL Receptors (LDL Receptor)IBA 03/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	3' Untranslated Regions (3' UTR)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 11/2018
1	omega-Chloroacetophenone (Mace)IBA 10/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 11/2014
1	Myosin Light Chains (Myosin Essential Light Chain)IBA 11/2014

Therapy/Procedure

4	Therapeutics 01/2023 - 11/2014
2	Mediterranean Diet 01/2021 - 12/2019
1	Myocardial Revascularization 01/2019